Clinical Characteristics and Risk Factors for Renal Cell Carcinoma after Kidney Transplantation

Abstract Background The objective of this study is to discuss clinical characteristics and treatments of hereditary leiomyomatosis renal cell carcinoma on the basis of 2 cases and to review recent literature, in order to present medical advances. Methods A 29-year old male patient came to our hospital because of a huge tumour on the right kidney. Enhanced CT showed that the tumour was about 15.5*10.5 cm, and was considered to be malignant. Another case was a 38-year old female patient. She complained was found to have a right kidney tumour in a routine physical examination. Enhanced CT showed an early-stage tumour of about 4.3*3.7 cm on the lower pole of the right kidney. The male patient underwent open radical nephrectomy and the female patient underwent laparoscopic radical nephrectomy and extensive retroperitoneal lymph node dissection. The two patients underwent genetic testing and were diagnosed as having hereditary leiomyomatosis with renal cell carcinoma. Results The postoperative pathology in both patients revealed type 2 papillary renal cell carcinoma but with different prognosis. The male patient suffered multiple metastasis 10 months post-operation. The metastatic tumour of the abdominal wall was resected to confirm recurrence and hereditary leiomyomatosis renal cell carcinoma was diagnosed by the genetic test. While the female patient had a specific family history and uterine leiomyomas, the genetic test helped us to identify hereditary leiomyomatosis renal cell carcinoma pre-operation. Because of the early diagnosis and timely treatment, the female patient was considered to have a good prognosis. Conclusion Hereditary leiomyomatosis renal cell carcinoma is a rare hereditary disease resulting from FH gene mutation. There are currently no effective treatments.Our cases demonstrate that hereditary leiomyomatosis renal cell carcinoma is a very aggressive disease. Early screening and surveillance are recommended for patients with a family history or who are at risk of hereditary leiomyomatosis renal cell carcinoma. Surgical and palliative therapy still play an important role in clinical treatment.

Download Full-text

A convention-radiomics CT nomogram for differentiating fat-poor angiomyolipoma from clear cell renal cell carcinoma

Scientific Reports ◽

10.1038/s41598-021-84244-3 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Yanqing Ma ◽

Weijun Ma ◽

Xiren Xu ◽

Zheng Guan ◽

Peipei Pang

Keyword(s):

Risk Factors ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Logistic Model ◽

Clear Cell ◽

Cell Renal Cell Carcinoma ◽

Entire Cohort ◽

Conventional Ct ◽

Radiomics Signature

AbstractThis study aimed to construct convention-radiomics CT nomogram containing conventional CT characteristics and radiomics signature for distinguishing fat-poor angiomyolipoma (fp-AML) from clear-cell renal cell carcinoma (ccRCC). 29 fp-AML and 110 ccRCC patients were enrolled and underwent CT examinations in this study. The radiomics-only logistic model was constructed with selected radiomics features by the analysis of variance (ANOVA)/Mann–Whitney (MW), correlation analysis, and Least Absolute Shrinkage and Selection Operator (LASSO), and the radiomics score (rad-score) was computed. The convention-radiomics logistic model based on independent conventional CT risk factors and rad-score was constructed for differentiating. Then the relevant nomogram was developed. Receiver operation characteristic (ROC) curves were calculated to quantify the accuracy for distinguishing. The rad-score of ccRCC was smaller than that of fp-AML. The convention-radioimics logistic model was constructed containing variables of enhancement pattern, VUP, and rad-score. To the entire cohort, the area under the curve (AUC) of convention-radiomics model (0.968 [95% CI 0.923–0.990]) was higher than that of radiomics-only model (0.958 [95% CI 0.910–0.985]). Our study indicated that convention-radiomics CT nomogram including conventional CT risk factors and radiomics signature exhibited better performance in distinguishing fp-AML from ccRCC.

Download Full-text

Clinical characteristics and outcomes in renal transplant recipients with renal cell carcinoma in the native kidney

The Korean Journal of Internal Medicine ◽

10.3904/kjim.2013.28.3.347 ◽

2013 ◽

Vol 28 (3) ◽

pp. 347 ◽

Cited By ~ 5

Author(s):

In O Sun ◽

Yu Mi Ko ◽

Eun Young Kim ◽

Kyung Seon Park ◽

Hong Soon Jung ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Renal Transplant ◽

Cell Carcinoma ◽

Renal Cell ◽

Clinical Characteristics ◽

Renal Transplant Recipients ◽

Transplant Recipients ◽

Native Kidney

Download Full-text

CLINICAL CHARACTERISTICS OF 7 RENAL CELL CARCINOMA PATIENTS DEVELOPING A SOLITARY PANCREATIC METASTASIS AFTER NEPHRECTOMY

The Japanese Journal of Urology ◽

10.5980/jpnjurol1989.86.1538 ◽

1995 ◽

Vol 86 (10) ◽

pp. 1538-1542 ◽

Cited By ~ 1

Author(s):

Testuro Onishi ◽

Yukihiko Ohishi ◽

Norio Iizuka ◽

Yasuyuki Suzuki ◽

Hiroshi Shirakawa ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Clinical Characteristics ◽

Pancreatic Metastasis

Download Full-text

Risk Factors for Ipsilateral Adrenal Involvement in Renal Cell Carcinoma

Urology ◽

10.1016/j.urology.2008.02.035 ◽

2008 ◽

Vol 72 (2) ◽

pp. 354-358 ◽

Cited By ~ 9

Author(s):

Keiichi Ito ◽

Hayakazu Nakazawa ◽

Ken Marumo ◽

Seiichiro Ozono ◽

Tatsuo Igarashi ◽

...

Keyword(s):

Risk Factors ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell

Download Full-text

Advanced and metastatic renal cell carcinoma – Ain Shams Clinical Oncology Department Experience

Journal of Solid Tumors ◽

10.5430/jst.v10n1p18 ◽

2020 ◽

Vol 10 (1) ◽

pp. 18

Author(s):

Ahmed Nagy ◽

Mona Kamal ◽

Hesham El Halawani

Keyword(s):

Risk Factors ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Clinical Oncology ◽

Renal Cell ◽

Older Patients ◽

Treatment Options ◽

Tumor Grade ◽

Kaplan Meier ◽

Younger Age

Background: Renal cell carcinoma is a rare tumor and till recently few treatment options were available. It is poorly understood why people develop RCC since only a few etiologic factors have been clinically identified as risk factors for RCC.Purpose: To analyze our experience at Ain Shams University Clinical Oncology department in Egypt with patients presenting with advanced renal cell carcinoma to provide a correlations between clinic-pathological factors, treatment and survival outcomes.Methodology: Retrospective review of the data of 54 patients who were diagnosed as RCC and presented to Ain Shams University Clinical Oncology department in Egypt from 1 May 2013 till 1 May 2015. Descriptive and clinic-pathological data were described using simple and relative frequencies. Survival outcome for the patients will be described using Kaplan Meier curves stratified according to morphology, age group and treatment received.Results: The sample included 54 patients (53.7% were males) of whom 14.3% were less than 40 years and 3.7% were elderly (≥ 70 years old). The median age was 55.5 years (SD ± 13.6 , range 19-71). Median PFS was 6.5 months (SD ± 12.3846 Range 43) while the median OS was 13 months (SD ± 12.161 Range 46). PFS in patients aged below 55.5 years was 9 months (95% CI=6.509-11.491) compared to 4 months (95% CI=2.704-5.296) in older patients (p = .004). PFS in patients who achieved PR after sunitinb was 17 months (95% CI=6.916-27.084) compared to 5 months (95% CI=3.699-6.301) in patients who didn’t achieved PR (p < .001). OS in patients aged below 55.5 years was 15 months (95% CI=9.131-20.869) compared to 11 months (95% CI=8.947-13.053) in older patients (p = .012). Favorable pathology status was associated with prolonged OS of 14 months (95% CI= 9.403-18.597) versus 11 months (95% CI=8.363-13.637) for unfavourable pathology status (p = .11). Low grades histopathogy was associated with prolonged OS of 44 months (95% CI= 38.456-49.544) versus 12 months (95% CI=10.077-13.923) for higher grades (p = < .001).Conclusion: Multivariate analyses supported a conclusion that younger age was an independent prognostic factor for survival along with other known risk factors such as tumor grade and pathology status.

Download Full-text